Small-Molecule PF4 Antagonists to Block Tetramerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for heparin-induced thrombocytopenia and thrombosis (HITT) are inadequate, leading to significant morbidity and mortality due to the formation of ultra-large complexes of platelet factor 4 (PF4) and heparin, which trigger platelet activation and thrombosis, with no specific therapies available to interrupt this pathophysiology.
Innovation Solution
Development of small molecule compounds that inhibit the tetramerization of PF4, disrupting the formation of ultra-large complexes and preventing platelet activation, thereby reducing the risk of thrombosis and thrombocytopenia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If heparin therapy is administered to prevent blood clots, then anticoagulation effect is improved, but heparin-induced thrombocytopenia and thrombosis (HITT) occurs as a harmful side effect
Solution Approach 1:
The patent extracts and targets the specific pathogenic mechanism of HITT by inhibiting PF4 tetramerization, separating the harmful immune complex formation from the beneficial anticoagulation effect of heparin
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that bind to PF4 and prevent tetramerization, thereby blocking the formation of ultra-large complexes without interfering with heparin's anticoagulant mechanism
2Reliability
If existing therapies are used to treat HITT, then general anticoagulation is provided, but specific pathophysiology of HITT is not addressed
Solution Approach 1:
The patent applies local quality by targeting the specific molecular interaction (PF4 tetramerization) that drives HITT pathophysiology, rather than providing general anticoagulation therapy
Solution Approach 2:
The patent changes the therapeutic parameter from general anticoagulation to specific inhibition of PF4 tetramerization, addressing the root cause of HITT with high potency compounds at μM level
3Reliability
If small molecule compounds are designed to inhibit PF4 tetramerization, then potency is improved, but complexity of compound structure increases
Solution Approach 1:
The patent optimizes compound parameters including molecular weight, logP, and functional groups to achieve high potency while maintaining drug-like properties and manageable structural complexity
Data Source
AI summary
The present application provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Y, R1, R2, R3 and R4 are described herein. The methods of using these compounds to inhibit tetramerization of PF4 and to treat the associated diseases and conditions, such as heparin-induced thrombocytopenia and thrombosis (HITT) and vaccine-induced immune thrombotic thrombocytopenia (VITT), methods of making these compounds, and pharmaceutical compositions containing these compounds are also disclosed.